

Open Access and Copyright License Status of Pharmaceutical Company-Supported Articles

Elin Bevan^a, Tim Koder^a, Valérie Philippon^b, Slávka Baróniková^c, Larisa Miller^d, William Gattrell^e and Tomas Rees^a ^aOxford PharmaGenesis, Oxford, UK; ^bTakeda Development Center Americas, Inc., Cambridge, MA, USA; ^cGalápagos NV, Mechelen, Belgium; ^dAlexion, AstraZeneca Rare Disease, Boston, MA, USA; ^elpsen, Abingdon, UK* *Affiliation at the time of abstract development

Presenting author: Valérie Philippon, valerie.philippon@ucb.com

- (e.g. journal article, review, letter).
- by using article type metadata supplied by Embase.
- scope of most OA policies.
- analyzed with the new method.³

- and CC BY (28%) (**Table 1**).



OA license type	Number of articles (%)
CC BY	2321 (28)
CC BY-NC	1606 (19)
CC BY-NC-ND	2400 (29)
No data ^a	1692 (21)
Other ^b	223 (3)
^a Bronze OA articles (free to read on the publisher's website, without a license that grants any other rights) almost never disclose a copyright license. Other missing data are mostly green OA (which have been archived in an OA repository separate to the publisher's site). ^b Author choice/editor's choice usage agreement: CC, CC BY-NC-SA, CC BY-SA, CC BY-ND;	

Presented at the 9th International Congress on Peer Review and Scientific Publication, September 8–10, 2022, Chicago, IL, USA Data previously presented at the 2022 Annual Meeting of the International Society for Medical Publication Professionals, May 9–11, 2022, Washington DC, USA





